Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells

Imagem de Miniatura
Arquivos
art_SAITO_PhosphatidylcholineDerived_Lipid_Mediators_The_Crosstalk_Between_Cancer_Cells_2022.PDF (4.85 MB)
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
Citação
FRONTIERS IN IMMUNOLOGY, v.13, article ID 768606, 24p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
To become resistant, cancer cells need to activate and maintain molecular defense mechanisms that depend on an energy trade-off between resistance and essential functions. Metabolic reprogramming has been shown to fuel cell growth and contribute to cancer drug resistance. Recently, changes in lipid metabolism have emerged as an important driver of resistance to anticancer agents. In this review, we highlight the role of choline metabolism with a focus on the phosphatidylcholine cycle in the regulation of resistance to therapy. We analyze the contribution of phosphatidylcholine and its metabolites to intracellular processes of cancer cells, both as the major cell membrane constituents and source of energy. We further extended our discussion about the role of phosphatidylcholine-derived lipid mediators in cellular communication between cancer and immune cells within the tumor microenvironment, as well as their pivotal role in the immune regulation of therapeutic failure. Changes in phosphatidylcholine metabolism are part of an adaptive program activated in response to stress conditions that contribute to cancer therapy resistance and open therapeutic opportunities for treating drug-resistant cancers.
Palavras-chave
lipid metabolism, phosphatidylcholine, lipid mediators, immunoregulation, immune microenvironment, cancer drug resistance
URI
https://observatorio.fm.usp.br/handle/OPI/50486
Referências
  1. Abalsamo L, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3151
  2. Aboagye EO, 1999, CANCER RES, V59, P80
  3. Ackerstaff E, 2001, CANCER RES, V61, P3599
  4. Al-Saffar NMS, 2018, BRIT J CANCER, V119, P1118, DOI 10.1038/s41416-018-0242-3
  5. Al-Saffar NMS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103835
  6. Al-Saffar NMS, 2010, CANCER RES, V70, P5507, DOI 10.1158/0008-5472.CAN-09-4476
  7. Andrejeva G, 2020, AUTOPHAGY, V16, P1044, DOI 10.1080/15548627.2019.1659608
  8. Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031
  9. Asim M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv371
  10. Bae S, 2014, CANCER RES, V74, P7442, DOI 10.1158/0008-5472.CAN-14-1835
  11. Bagnoli M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00153
  12. Rizzo A, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-020-01794-6
  13. Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715
  14. RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506
  15. Sahu RP, 2016, ONCOTARGET, V7, P20788, DOI 10.18632/oncotarget.7878
  16. Sahu RP, 2014, CANCER RES, V74, P7069, DOI 10.1158/0008-5472.CAN-14-2043
  17. Sahu RP, 2012, CARCINOGENESIS, V33, P1360, DOI 10.1093/carcin/bgs152
  18. Saito RF, 2021, NANOMED-NANOTECHNOL, V36, DOI 10.1016/j.nano.2021.102418
  19. Samadi N, 2009, ONCOGENE, V28, P1028, DOI 10.1038/onc.2008.442
  20. Sanchez-Lopez E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.453
  21. Beloueche-Babari M, 2010, ONCOTARGET, V1, P185
  22. Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146
  23. Sarri E, 2006, BIOCHEM J, V394, P325, DOI 10.1042/BJ20050834
  24. Schlaepfer IR, 2012, MOL CELL ENDOCRINOL, V363, P111, DOI 10.1016/j.mce.2012.08.005
  25. SCHLAGER SI, 1979, J NATL CANCER I, V63, P1475
  26. Shah T, 2010, NMR BIOMED, V23, P633, DOI 10.1002/nbm.1510
  27. Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141
  28. Sharma U, 2011, NMR BIOMED, V24, P700, DOI 10.1002/nbm.1654
  29. Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616
  30. Shindou H, 2007, J BIOL CHEM, V282, P6532, DOI 10.1074/jbc.M609641200
  31. Shindou H, 2009, J LIPID RES, V50, pS46, DOI 10.1194/jlr.R800035-JLR200
  32. SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506
  33. Iorio E, 2021, EUR RADIOL EXP, V5, DOI 10.1186/s41747-020-00192-z
  34. Beloueche-Babari M, 2009, MOL CANCER THER, V8, P1305, DOI 10.1158/1535-7163.MCT-09-0039
  35. SMITH TAD, 1991, BRIT J CANCER, V64, P821, DOI 10.1038/bjc.1991.407
  36. Sola-Leyva A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40885-z
  37. Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022
  38. Spadaro F, 2008, CANCER RES, V68, P6541, DOI 10.1158/0008-5472.CAN-07-6763
  39. St John MA, 2015, LARYNGOSCOPE, V125, pS1, DOI 10.1002/lary.24998
  40. Stadlbauer A, 2006, RADIOLOGY, V238, P958, DOI 10.1148/radiol.2382041896
  41. Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657
  42. Sulciner ML, 2018, CANCER METAST REV, V37, P557, DOI 10.1007/s10555-018-9754-9
  43. Sulciner ML, 2018, J EXP MED, V215, P115, DOI 10.1084/jem.20170681
  44. Iorio E, 2010, CANCER RES, V70, P2126, DOI 10.1158/0008-5472.CAN-09-3833
  45. Sun H, 2009, WORLD J GASTROENTERO, V15, P4547, DOI 10.3748/wjg.15.4547
  46. Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118
  47. Sun XT, 2018, INT J MOL MED, V42, P1203, DOI 10.3892/ijmm.2018.3744
  48. Take Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00324
  49. Tang XY, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158716
  50. Tang XY, 2020, MOL CANCER THER, V19, P63, DOI 10.1158/1535-7163.MCT-19-0386
  51. Thukral L, 2015, BIOPHYS J, V109, P2067, DOI 10.1016/j.bpj.2015.09.022
  52. Ting YLT, 1996, ANTICANCER RES, V16, P1381
  53. Tong DL, 2018, CANCER METAST REV, V37, P355, DOI 10.1007/s10555-018-9752-y
  54. Travers JB, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.624132
  55. Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219
  56. Tumanov S, 2017, CURR OPIN BIOTECH, V43, P127, DOI 10.1016/j.copbio.2016.11.008
  57. Uchida H, 1999, ANTICANCER RES, V19, P671
  58. Bhave SR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00236
  59. Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060
  60. van Asten JJA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0458-4
  61. Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285
  62. Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230
  63. Vanpouille C, 2009, EUR J NUCL MED MOL I, V36, P1256, DOI 10.1007/s00259-009-1101-5
  64. Venkatraman G, 2015, FASEB J, V29, P772, DOI 10.1096/fj.14-262659
  65. Wallitt KL, 2017, RADIOGRAPHICS, V37, P1512, DOI 10.1148/rg.2017170035
  66. Jacobs MA, 2004, J MAGN RESON IMAGING, V19, P68, DOI 10.1002/jmri.10427
  67. WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
  68. Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
  69. Watanabe S, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050104
  70. Bi JF, 2019, CELL METAB, V30, P525, DOI 10.1016/j.cmet.2019.06.014
  71. Wen SM, 2020, ONCOGENE, V39, P6556, DOI 10.1038/s41388-020-01456-z
  72. Williams SNO, 1998, MAGNET RESON MED, V40, P411, DOI 10.1002/mrm.1910400311
  73. Witney TH, 2012, CLIN CANCER RES, V18, P1063, DOI 10.1158/1078-0432.CCR-11-2462
  74. Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249
  75. Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003
  76. Xu Y, 2018, CANCERS, V10, DOI 10.3390/cancers10070227
  77. Jagannathan NR, 2001, BRIT J CANCER, V84, P1016, DOI 10.1054/bjoc.2000.1711
  78. Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
  79. Yao YF, 2020, BIOL REV, V95, P911, DOI 10.1111/brv.12592
  80. Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135
  81. Ylostalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191
  82. BJORKOY G, 1995, J BIOL CHEM, V270, P21299
  83. Yoshimoto M, 2001, NUCL MED BIOL, V28, P117, DOI 10.1016/S0969-8051(00)00195-5
  84. Yu Y, 2014, BRIT J CANCER, V111, P515, DOI 10.1038/bjc.2014.323
  85. Zakian KL, 2005, RADIOLOGY, V234, P804, DOI 10.1148/radiol.2343040363
  86. Zeisel SH, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050445
  87. Zeisel SH, 2012, MUTAT RES-FUND MOL M, V733, P34, DOI 10.1016/j.mrfmmm.2011.10.008
  88. Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
  89. Zeng RL, 2017, GENET TEST MOL BIOMA, V21, P641, DOI 10.1089/gtmb.2017.0060
  90. Zhang Q, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00071
  91. Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200
  92. Boilard E, 2018, J LIPID RES, V59, P2037, DOI 10.1194/jlr.R084640
  93. Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928
  94. Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r
  95. Bozzo F, 2009, CHEM-BIOL INTERACT, V182, P183, DOI 10.1016/j.cbi.2009.08.006
  96. CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645
  97. Cai M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.355
  98. CARNERO A, 1994, ONCOGENE, V9, P1387
  99. Janardhan S, 2006, CURR MED CHEM, V13, P1169, DOI 10.2174/092986706776360923
  100. Chaithra VH, 2018, J LIPID RES, V59, P2063, DOI 10.1194/jlr.M085704
  101. Chammas Roger, 2017, Nat Rev Cancer, V17, P253, DOI 10.1038/nrc.2017.15
  102. Chang HC, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-01000-2
  103. Chen JLY, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000293
  104. Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257
  105. Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565
  106. Cheng ML, 2017, NEOPLASIA, V19, P617, DOI 10.1016/j.neo.2017.05.004
  107. Choi JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083866
  108. Chung YL, 2003, J NATL CANCER I, V95, P1624, DOI 10.1093/jnci/djg084
  109. Chung YL, 2008, NEOPLASIA, V10, P303, DOI 10.1593/neo.07834
  110. JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006
  111. Cotte AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02732-5
  112. Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668
  113. da Silva IA, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5482768
  114. da Silva IA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00010
  115. DALY PF, 1987, J BIOL CHEM, V262, P14875
  116. Danishad KKA, 2010, NMR BIOMED, V23, P233, DOI 10.1002/nbm.1436
  117. de la Cueva A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064961
  118. de Oliveira SI, 2006, PROSTAG OTH LIPID M, V80, P62, DOI 10.1016/j.prostaglandins.2006.04.002
  119. Desoubzdanne D, 2010, ANAL BIOANAL CHEM, V398, P2723, DOI 10.1007/s00216-010-4196-4
  120. Dixon SJ, 2015, ACS CHEM BIOL, V10, P1604, DOI 10.1021/acschembio.5b00245
  121. Johnson AM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.595498
  122. DUBOIS G, 1992, BIOMED PHARMACOTHER, V46, P485, DOI 10.1016/0753-3322(92)90006-S
  123. Dupont N, 2014, CURR BIOL, V24, P609, DOI 10.1016/j.cub.2014.02.008
  124. Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293
  125. Esseridou A, 2011, INVEST RADIOL, V46, P377, DOI 10.1097/RLI.0b013e31821690ef
  126. EVELHOCH JL, 1987, CANCER RES, V47, P3396
  127. Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473
  128. Fei BW, 2010, J NUCL MED, V51, P130, DOI 10.2967/jnumed.109.067579
  129. Feng Y, 2020, J INFLAMM-LOND, V17, DOI 10.1186/s12950-020-00254-4
  130. Ferracini M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/950273
  131. Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E
  132. Banchio C, 2006, J BIOL CHEM, V281, P10010, DOI 10.1074/jbc.M513503200
  133. Flores I, 2000, FASEB J, V14, P1873
  134. Foster DA, 2003, MOL CANCER RES, V1, P789
  135. Foster DA, 2013, TRENDS ENDOCRIN MET, V24, P272, DOI 10.1016/j.tem.2013.02.003
  136. Fox LM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000228
  137. Frankel A, 1996, CLIN CANCER RES, V2, P1307
  138. Fujii R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-40
  139. Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055
  140. Fuss TL, 2016, METABOLITES, V6, DOI 10.3390/metabo6010011
  141. GALONS JP, 1995, MAGN RESON MED, V33, P422, DOI 10.1002/mrm.1910330317
  142. Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524
  143. Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]
  144. Giabbai B, 2005, J IMMUNOL, V175, P977, DOI 10.4049/jimmunol.175.2.977
  145. Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337
  146. Gilligan MM, 2019, P NATL ACAD SCI USA, V116, P6292, DOI 10.1073/pnas.1804000116
  147. Glunde K, 2008, CANCER RES, V68, P172, DOI 10.1158/0008-5472.CAN-07-2678
  148. Glunde K, 2006, MOL PHARMACEUT, V3, P496, DOI 10.1021/mp060067e
  149. Glunde K, 2015, EXPERT REV MOL DIAGN, V15, P735, DOI 10.1586/14737159.2015.1039515
  150. Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162
  151. Glunde K, 2011, SEMIN ONCOL, V38, P26, DOI 10.1053/j.seminoncol.2010.11.001
  152. Gogiashvili M, 2019, METABOLITES, V9, DOI 10.3390/metabo9020019
  153. Gokhale S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13060911
  154. Kamphorst JJ, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-23
  155. Granata A, 2014, BRIT J CANCER, V110, P330, DOI 10.1038/bjc.2013.729
  156. Gualde N, 2004, IMMUNOL CELL BIOL, V82, P353, DOI 10.1111/j.0818-9641.2004.01251.x
  157. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  158. Hara T, 2006, NUCL MED BIOL, V33, P977, DOI 10.1016/j.nucmedbio.2006.08.002
  159. Harayama T, 2009, J LIPID RES, V50, P1824, DOI 10.1194/jlr.M800500-JLR200
  160. Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255
  161. Harizi H, 2013, CELL MOL IMMUNOL, V10, P213, DOI 10.1038/cmi.2013.1
  162. He XH, 2013, WORLD J GASTROENTERO, V19, P4200, DOI 10.3748/wjg.v19.i26.4200
  163. Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207
  164. Hernando E, 2009, ONCOGENE, V28, P2425, DOI 10.1038/onc.2009.91
  165. KAPLAN O, 1990, BIOCHEM BIOPH RES CO, V169, P383, DOI 10.1016/0006-291X(90)90343-L
  166. Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889
  167. Hirai K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155190
  168. Holt D, 2011, CANCER IMMUNOL IMMUN, V60, P1577, DOI 10.1007/s00262-011-1064-9
  169. Hou WZ, 2016, CANCER CELL, V30, P108, DOI 10.1016/j.ccell.2016.05.012
  170. Hu L, 2016, ONCOTARGET, V7, P66660, DOI 10.18632/oncotarget.11433
  171. Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385
  172. Inazu M, 2014, BIOPHARM DRUG DISPOS, V35, P431, DOI 10.1002/bdd.1892
  173. Inazu M, 2013, PHARMACOL RES, V76, P119, DOI 10.1016/j.phrs.2013.07.011
  174. Katz-Brull R, 2002, JNCI-J NATL CANCER I, V94, P1197
  175. KENNEDY EP, 1956, J BIOL CHEM, V222, P193
  176. Kim J, 2018, INT J ONCOL, V52, P613, DOI 10.3892/ijo.2017.4227
  177. KISS Z, 1995, FEBS LETT, V360, P165, DOI 10.1016/0014-5793(95)00094-P
  178. Koga MM, 2013, PROSTAG LEUKOTR ESS, V89, P319, DOI 10.1016/j.plefa.2013.09.003
  179. Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z
  180. Kovacheva VP, 2007, J BIOL CHEM, V282, P31777, DOI 10.1074/jbc.M705539200
  181. Bansal A, 2008, EUR J NUCL MED MOL I, V35, P1192, DOI 10.1007/s00259-008-0736-y
  182. Kumar M, 2015, MOL CANCER THER, V14, P899, DOI 10.1158/1535-7163.MCT-14-0775
  183. Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004
  184. Kurhanewicz J, 1996, RADIOLOGY, V200, P489, DOI 10.1148/radiology.200.2.8685346
  185. Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034
  186. Kwee SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046591
  187. Lacal JC, 2015, MOL CANCER THER, V14, P31, DOI 10.1158/1535-7163.MCT-14-0531
  188. Bachi ALL, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/610371
  189. Lagadari M, 2009, INT IMMUNOL, V21, P667, DOI 10.1093/intimm/dxp035
  190. LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O
  191. Lawrence T, 2007, TRENDS PHARMACOL SCI, V28, P162, DOI 10.1016/j.tips.2007.02.003
  192. Bansal A, 2012, J LIPID RES, V53, P149, DOI 10.1194/jlr.M021030
  193. Lee SC, 2020, CANCERS, V12, DOI 10.3390/cancers12051202
  194. Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422-019-0263-3
  195. Li DS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00216-5
  196. Li SR, 2021, CHEM COMMUN, V57, P1372, DOI 10.1039/d0cc08011j
  197. Lin XM, 2017, GASTROENTEROLOGY, V152, P1187, DOI 10.1053/j.gastro.2016.12.033
  198. Liu X, 2021, ONCOGENE, V40, P4521, DOI 10.1038/s41388-021-01880-9
  199. Liu XJ, 2013, WORLD J GASTROENTERO, V19, P6265, DOI 10.3748/wjg.v19.i37.6265
  200. Lovey J, 2013, CANCER LETT, V335, P495, DOI 10.1016/j.canlet.2013.03.012
  201. Mahic M, 2006, J IMMUNOL, V177, P246, DOI 10.4049/jimmunol.177.1.246
  202. Marathe GK, 2020, PROSTAG OTH LIPID M, V151, DOI 10.1016/j.prostaglandins.2020.106478
  203. Bekdash RA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122995
  204. Mariotto E, 2018, CANCERS, V10, DOI 10.3390/cancers10100391
  205. Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987
  206. Matas-Rico E., 2020, BIORXIV, DOI [10.1101/2020.02.26.966291, DOI 10.1101/2020.02.26.966291]
  207. Mathew D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01159
  208. Mazarico JM, 2016, MOL CANCER THER, V15, P323, DOI 10.1158/1535-7163.MCT-15-0214
  209. Meisamy S, 2004, RADIOLOGY, V233, P424, DOI 10.1148/radiol.2332031285
  210. Mignion L, 2016, INT J CANCER, V138, P2043, DOI 10.1002/ijc.29932
  211. Minami K, 2019, BIOCHEM BIOPH RES CO, V517, P359, DOI 10.1016/j.bbrc.2019.07.092
  212. Miyake T, 2012, ONCOGENE, V31, P1431, DOI 10.1038/onc.2011.332
  213. Moessinger C, 2011, J BIOL CHEM, V286, P21330, DOI 10.1074/jbc.M110.202424
  214. Beloueche-Babari M, 2006, MOL CANCER THER, V5, P187, DOI 10.1158/1535-7163.MCT-03-0220
  215. Molendijk J, 2020, MOL OMICS, V16, P6, DOI 10.1039/c9mo00128j
  216. Montopoli M, 2011, CURR CANCER DRUG TAR, V11, P226, DOI 10.2174/156800911794328501
  217. Mori N, 2007, CANCER RES, V67, P11284, DOI 10.1158/0008-5472.CAN-07-2728
  218. Mori N, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00262
  219. Morse DL, 2007, MAGN RESON MED, V58, P270, DOI 10.1002/mrm.21333
  220. Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x
  221. Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x
  222. Nikolaou S, 2020, J PATHOL, V250, P612, DOI 10.1002/path.5395
  223. NISHIO K, 1992, J CLIN INVEST, V89, P1622, DOI 10.1172/JCI115758
  224. Nishiyama-Naruke A, 2000, AM J PHYSIOL-CELL PH, V278, pC554, DOI 10.1152/ajpcell.2000.278.3.C554
  225. Beloueche-Babari M, 2005, CANCER RES, V65, P3356, DOI 10.1158/0008-5472.CAN-03-2981
  226. Noble AR, 2018, BRIT J CANCER, V118, P189, DOI 10.1038/bjc.2017.391
  227. Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1
  228. Nunn AVW, 1996, FEBS LETT, V392, P295, DOI 10.1016/0014-5793(96)00839-3
  229. Ogasawara Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18153-w
  230. Oka M, 2003, J INVEST DERMATOL, V121, P69, DOI 10.1046/j.1523-1747.2003.12300.x
  231. Onuchic AC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/175408
  232. Paris L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2575
  233. Penrose H, 2016, BIOCHEM BIOPH RES CO, V469, P370, DOI 10.1016/j.bbrc.2015.11.119
  234. Pisanu ME, 2014, BRIT J CANCER, V110, P625, DOI 10.1038/bjc.2013.758
  235. Podo F, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00171
  236. Beloueche-Babari M, 2012, CANCER RES, V72, P990, DOI 10.1158/0008-5472.CAN-11-2688
  237. Podo F, 2011, NMR BIOMED, V24, P648, DOI 10.1002/nbm.1658
  238. Pogribny IP, 2009, MUTAT RES-FUND MOL M, V669, P56, DOI 10.1016/j.mrfmmm.2009.05.003
  239. Prabhakar NR, 2001, J APPL PHYSIOL, V90, P1986, DOI 10.1152/jappl.2001.90.5.1986
  240. Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114
  241. de Molina AR, 2012, CURR CANCER DRUG TAR, V12, P617
  242. Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144
  243. Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6
  244. RAMU A, 1991, BIOCHEM PHARMACOL, V41, P1455, DOI 10.1016/0006-2952(91)90561-I
  245. RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959
  246. Reinartz S, 2019, MOL ONCOL, V13, P185, DOI 10.1002/1878-0261.12396
  247. Beloueche-Babari M, 2011, CELL CYCLE, V10, P2883, DOI 10.4161/cc.10.17.17192
  248. Riedel S, 2016, PROSTAG LEUKOTR ESS, V109, P39, DOI 10.1016/j.plefa.2016.04.006

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/07